What question did this study set out to answer?

To assess whether adding molnupiravir or nirmatrelvir–ritonavir to usual care improves clinical outcomes compared with usual care alone in patients hospitalized with COVID-19.

May 15, 2025ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Open Access

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

View Full Paper

Ask AI

Bookmark

To assess whether adding molnupiravir or nirmatrelvir–ritonavir to usual care improves clinical outcomes compared with usual care alone in patients hospitalized with COVID-19.
Randomised, controlled, open-label platform trial (RECOVERY) conducted in hospitalized patients with COVID-19.
Patients were allocated to receive either molnupiravir plus usual care, nirmatrelvir–ritonavir plus usual care, or usual care alone.
Evaluation centered on key clinical outcomes including mortality, hospital discharge time, and requirement for invasive mechanical ventilation.
Specific quantitative event rates and treatment effect sizes were omitted in the provided text.

Implication

Randomized trial reveals clinical outcomes of molnupiravir or nirmatrelvir–ritonavir in hospitalized COVID-19 patients, indicating the role of antivirals alongside usual care.

Abstract

UK Research and Innovation (UK Medical Research Council), the National Institute for Health and Care Research, and the Wellcome Trust.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abani et al. (2025) studied this question.

synapsesocial.com/papers/69da539b84371aa676a3d12f https://doi.org/10.1016/s1473-3099(25)00093-3

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals clinical outcomes of molnupiravir or nirmatrelvir–ritonavir in hospitalized COVID-19 patients, indicating the role of antivirals alongside usual care.

Abstract

UK Research and Innovation (UK Medical Research Council), the National Institute for Health and Care Research, and the Wellcome Trust.

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading